Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults

Viral Immunology

Volumn 20, Issue 3, 2007, Pages 379-388

  Zhou, Wendi ^a   Sharma, Madeva ^a   Martinez, Joy ^a   Srivastava, Tumul ^a   Diamond, Don J ^a   Knowles, Wendy ^b   Lacey, Simon F ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CD40 LIGAND; CYTOKINE; GAMMA INTERFERON; GRANZYME A; GRANZYME B; HLA A ANTIGEN; POLYPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN; VIRUS T ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY TRANSPLANTATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYOMA VIRUS; VIRUS INFECTION; VIRUS REACTIVATION;

ADULT; ANTIGENS, VIRAL; BK VIRUS; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL DEGRANULATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; GRANZYMES; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; POLYOMAVIRUS INFECTIONS; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR VIRUS INFECTIONS;

BK POLYOMAVIRUS; MIRIDAE;

EID: 35348891071     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0030     Document Type: Article

References (40)

1. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, and Miller E: Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-123.
2. Kleinschmidt-DeMasters BK, and Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.
3. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, and Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381.
4. Van Assche G, Van Ranst, M., Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, and Rutgeerts P: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368.
5. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, and Trofe J: Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005;79:1277-1286.
6. Ramos E, and Hirsch HH: Polyomavirus-associated nephropathy: Updates on a persisting challenge. Transpl Infect Dis 2006;8:59-61.
7. Hirsch HH, Drachenberg CB, Steiger J, and Ramos E: Polyomavirus- associated nephropathy in renal transplantation: Critical issues of screening and management. Adv Exp Med Biol 2006;577:160-173.
8. Scantlebury V, Shapiro R, Randhawa P, Weck KE, and Vats A: Cidofovir: A method of treatment for BK virus-associated transplant nephropathy. Graft 2002;5(Suppl):S82-S87.
9. Kadambi PV, Josephson MA, Williams J, Corey L, Jerome KR, Meehan SM, and Limaye AP: Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003;3:186-191.
10. Purighalla R, Shapiro R, McCauley J, and Randhawa P: BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995;26:671-673.
11. Josephson MA, Williams JW, Chandraker A, and Randhawa PS: Polyomavirus-associated nephropathy: Update on antiviral strategies. Transpl Infect Dis 2006;8:95-101.
12. Chandraker A, Ali S, and Drachenberg CB: Use of fluoroquinolones to treat BK infection in renal transplant recipients [abstract]. Am J Transplant 2004;4(Suppl 8):587.
13. Krymskaya L, Sharma MC, Martinez J, Haq W, Huang EC, Limaye AP, Diamond DJ, and Lacey SF: Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 2005;79:11170-11178.
14. Sharma MC, Zhou W, Martinez J, Krymskaya L, Srivastava T, Haq W, Diamond DJ, and Lacey SF: Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. Virology 2006;350:128-136.
15. Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy-Chaudhury P, Kuroda MJ, Woodle ES, Khalili K, and Koralnik IJ: Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 2006;80:3495-3505.
16. Du Pasquier RA, Clark KW, Smith PS, Joseph JT, Mazullo JM, De Girolami U, Letvin NL, and Koralnik IJ: JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol 2001;7:318-322.
17. + progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002;168:499-504.
18. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, and Koralnik IJ: A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127:1970-1978.
19. + T cells sensitized to BK virus large T antigen in healthy volunteers and kidney transplant recipients. Hum Immunol 2006;67:298-302.
20. +/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. J Transl Med 2006;4:47.
21. Li J, Melenhorst J, Hensel N, Rezvani K, Sconocchia G, Kilical Y, Hou J, Curfman B, Major E, and Barrett AJ: T-cell responses to peptide fragments of the BK virus T antigen: Implications for cross-reactivity of immune response to JC virus. J Gen Virol 2006;87:2951-2960.
22. +, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J. Immunol. 2004;173:1834-1841.
23. +, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 2004;103:2238-2247.
24. + cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 2002;99:3302-3309.
25. Jellison ER, Kim SK, and Welsh RM: Cutting Edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 2005;174:614-618.
26. Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, Kuus-Reichel K, Chang JC, Summers A, Clay TM, Morse MA, Lyerly HK, DeLaRosa C, Ankerst DP, and Disis ML: Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol 2005;6:17.
27. + T cells with diverse cytokine profiles. Nat Med 2005;11:1113-1117.
28. + T cells specific for defined antigens according to CD154 expression. Nat Med 2005;11:1118-1124.
29. + T cells. Blood 2006;107:4781-4789.
30. + T cells producing both interferon-γ and tumor necrosis factor-α. Blood 2004;104:487-494.
31. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR, et al.: Molecular and biological characterization of a murine ligand for CD40. Nature 1992;357:80-82.
32. + T cells. J Immunol 1993;151:2497-2510.
33. + cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. J Infect Dis 2005;191:977-984.
34. Lacey SF, La Rosa C, Zhou W, Sharma MC, Martinez J, Krishnan A, Gallez-Hawkins G, Thao L, Longmate J, Spielberger R, Forman SJ, Limaye A, Zaia JA, and Diamond DJ: Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis 2006;194:1410-1421.
35. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
36. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, and Lee PP: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003;9:1377-1382.
37. + T-cells: The holy grail? Clin Exp Immunol 2004;138:10-13.
38. Hammer MH, Brestrich G, Andree H, Engelmann E, Rosenberger C, Tillmann H, Zwinger S, Babel N, Nickel P, Volk HD, and Reinke P: HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant 2006;6:625-631.
39. Comoli P, Basso S, Azzi A, Moretta A, De Santis R, Del Galdo F, De Palma R, Valente U, Nocera A, Perfumo F, Locatelli F, Maccario R, and Ginevri F: Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003;14:3197-3204.
40. Imperiale MJ: The human polyomaviruses: an overview. In: Human Polyomaviruses: Molecular and Clinical Perspectives (Khalili K and Stoner GL, eds.). Wiley-Liss, New York, 2001, pp. 53-71.